Log in

NASDAQ:OPGNOpGen Stock Price, Forecast & News

+0.01 (+0.51 %)
(As of 06/3/2020 04:00 PM ET)
Today's Range
Now: $1.98
50-Day Range
MA: $2.14
52-Week Range
Now: $1.98
Volume1.05 million shs
Average Volume718,414 shs
Market Capitalization$29.84 million
P/E RatioN/A
Dividend YieldN/A
OpGen, Inc., a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance in urine specimens or bacterial colonies isolated from urine and other body sites; and QuickFISH and PNA FISH products, which are FDA-cleared and CE-marked diagnostic test designed to detect antimicrobial- resistant pathogens. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics offerings, which combine clinical lab test results with patient and hospital information, and provide analytics and insights to enable manage MDROs in the hospital and patient care environment. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.
Read More
OpGen logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars

Industry, Sector and Symbol

Industry Medical laboratories
Current SymbolNASDAQ:OPGN



Sales & Book Value

Annual Sales$3.50 million
Book Value$0.77 per share


Net Income$-12,450,000.00
Net Margins-405.10%


Market Cap$29.84 million
Next Earnings Date8/5/2020 (Estimated)
OptionableNot Optionable

Receive OPGN News and Ratings via Email

Sign-up to receive the latest news and ratings for OPGN and its competitors with MarketBeat's FREE daily newsletter.

OpGen (NASDAQ:OPGN) Frequently Asked Questions

How has OpGen's stock been impacted by COVID-19 (Coronavirus)?

OpGen's stock was trading at $2.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, OPGN shares have decreased by 4.3% and is now trading at $1.98. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of OpGen?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for OpGen.

When is OpGen's next earnings date?

OpGen is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for OpGen.

How were OpGen's earnings last quarter?

OpGen Inc (NASDAQ:OPGN) posted its quarterly earnings data on Thursday, May, 7th. The medical research company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by $0.14. The medical research company earned $0.62 million during the quarter. OpGen had a negative net margin of 405.10% and a negative return on equity of 241.40%. View OpGen's earnings history.

When did OpGen's stock split? How did OpGen's stock split work?

OpGen's stock reverse split on the morning of Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.

What guidance has OpGen issued on next quarter's earnings?

OpGen issued an update on its first quarter 2020 Pre-Market earnings guidance on Tuesday, April, 14th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $617K - 617K, compared to the consensus revenue estimate of $800K.

What price target have analysts set for OPGN?

1 analysts have issued 12 month price targets for OpGen's stock. Their forecasts range from $20.00 to $20.00. On average, they expect OpGen's share price to reach $20.00 in the next twelve months. This suggests a possible upside of 910.1% from the stock's current price. View analysts' price targets for OpGen.

Has OpGen been receiving favorable news coverage?

News coverage about OPGN stock has trended negative recently, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. OpGen earned a coverage optimism score of -2.8 on InfoTrie's scale. They also gave headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutOpGen.

Are investors shorting OpGen?

OpGen saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 509,600 shares, an increase of 7.4% from the April 30th total of 474,600 shares. Based on an average daily volume of 2,530,000 shares, the short-interest ratio is presently 0.2 days. Currently, 5.0% of the company's shares are sold short. View OpGen's Current Options Chain.

Who are some of OpGen's key competitors?

What other stocks do shareholders of OpGen own?

Who are OpGen's key executives?

OpGen's management team includes the following people:
  • Mr. Evan Jones, Chairman & CEO (Age 62)
  • Mr. Timothy C. Dec, CFO & Corp. Sec. (Age 60)
  • Mr. Vadim Sapiro, Chief Information Officer (Age 48)
  • Mr. Michael Farmer, VP of Marketing
  • Dr. G. Terrance Walker Ph.D., Sr. VP of R&D (Age 60)

When did OpGen IPO?

(OPGN) raised $17 million in an initial public offering (IPO) on Tuesday, May 5th 2015. The company issued 2,900,000 shares at a price of $5.50-$6.50 per share. Maxim Group served as the underwriter for the IPO and National Securities was co-manager.

What is OpGen's stock symbol?

OpGen trades on the NASDAQ under the ticker symbol "OPGN."

Who are OpGen's major shareholders?

OpGen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (0.13%), Jane Street Group LLC (0.09%) and UBS Group AG (0.09%). Company insiders that own OpGen stock include Evan/ Fa Jones and NV In Liquidation Curetis. View institutional ownership trends for OpGen.

Which major investors are buying OpGen stock?

OPGN stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Jane Street Group LLC, and UBS Group AG. View insider buying and selling activity for OpGen.

How do I buy shares of OpGen?

Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is OpGen's stock price today?

One share of OPGN stock can currently be purchased for approximately $1.98.

How big of a company is OpGen?

OpGen has a market capitalization of $29.84 million and generates $3.50 million in revenue each year. The medical research company earns $-12,450,000.00 in net income (profit) each year or ($6.90) on an earnings per share basis. OpGen employs 44 workers across the globe.

What is OpGen's official website?

The official website for OpGen is www.opgen.com.

How can I contact OpGen?

OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company can be reached via phone at 240-813-1260 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.